+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Status Epilepticus Drug"

Status Epilepticus - Pipeline Insight, 2024 - Product Thumbnail Image

Status Epilepticus - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Refractory status epilepticus - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory status epilepticus - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Status Epilepticus - Epidemiology Forecast - 2032 - Product Thumbnail Image

Status Epilepticus - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Status Epilepticus Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Status Epilepticus Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • August 2020
  • 99 Pages
  • Global
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Status epilepticus (SE) is a medical emergency characterized by a prolonged seizure or series of seizures without full recovery of consciousness in between. It is a life-threatening condition that requires immediate medical attention. SE is a major cause of morbidity and mortality in the Central Nervous System (CNS) drug market. The SE drug market is composed of a variety of drugs used to treat the condition, including benzodiazepines, barbiturates, and anticonvulsants. These drugs are used to control seizures, reduce the risk of recurrence, and prevent further neurological damage. The SE drug market is highly competitive, with a number of companies offering a range of products. Some of the major players in the SE drug market include Pfizer, GlaxoSmithKline, Sanofi, Novartis, and Johnson & Johnson. These companies offer a range of products, including benzodiazepines, barbiturates, and anticonvulsants, to treat SE. Show Less Read more